Novartis' Chinese vaccine presence boosted by acquisition
This article was originally published in Scrip
Executive Summary
Novartis has completed the acquisition of an 85% stake in the Chinese vaccines company Zhejiang Tianyuan. The acquisition was first proposed in 2009 at a purchase price of Yuan850 million (around $130 million), but required Chinese regulatory and government approvals.